Analyst Price Targets — VKTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 28, 2026 11:41 am | — | Lake Street | $89.00 | $31.66 | TheFly | Viking Therapeutics initiated with a Buy at Lake Street |
| May 27, 2026 10:08 am | Gregory Renza | Truist Financial | $83.00 | $30.80 | StreetInsider | Truist Securities Assumes Viking Therapeutic (VKTX) at Buy |
| April 30, 2026 1:11 pm | — | Morgan Stanley | $95.00 | $30.39 | TheFly | Viking Therapeutics price target lowered to $95 from $99 at Morgan Stanley |
| April 30, 2026 11:54 am | Steve Seedhouse | Cantor Fitzgerald | $100.00 | $31.33 | TheFly | Viking Therapeutics price target lowered to $100 from $105 at Cantor Fitzgerald |
| March 12, 2026 4:48 pm | Roger Song | Jefferies | $101.00 | $35.47 | StreetInsider | Jefferies Reiterates Buy Rating on Viking Therapeutic (VKTX): "VKTX is in an execution mode this year" |
| February 12, 2026 1:16 pm | Michael Ulz | Morgan Stanley | $99.00 | $31.07 | TheFly | Viking Therapeutics price target lowered to $99 from $102 at Morgan Stanley |
| November 12, 2025 11:43 am | Edward Nash | Canaccord Genuity | $107.00 | $40.60 | StreetInsider | Viking Therapeutic (VKTX) PT Raised to $107 at Canaccord Genuity |
| October 29, 2025 9:33 am | Edward Nash | Canaccord Genuity | $106.00 | $34.93 | TheFly | Canaccord starts Viking Therapeutics with Buy on obesity potential |
| October 23, 2025 12:05 pm | — | Morgan Stanley | $102.00 | $31.42 | TheFly | Viking Therapeutics price target raised to $102 from $98 at Morgan Stanley |
| October 23, 2025 11:16 am | — | Cantor Fitzgerald | $105.00 | $31.42 | TheFly | Viking Therapeutics offered 'transformative' Q3 update, says Cantor Fitzgerald |
Latest News for VKTX
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $37.08, representing a +1.95% change from its previous close.
VKTX's Q2 report could hinge on VK2735 pipeline updates as investors await progress on obesity studies and maintenance dosing plans.
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Viking Therapeutics, Inc. (NASDAQ: VKTX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Viking Therapeutics, Inc. (NASDAQ: VKTX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
Viking Therapeutics, Inc. (VKTX) reached $36.37 at the closing of the latest trading day, reflecting a -3.81% change compared to its last close.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VKTX.
U.S. House Trading
No House trades found for VKTX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.